Vault-13

Logos Global Management LP

San Francisco, CA · CIK 1792126 · 13F filing filed 2022-08-15

SEC-registered investment adviser since 2019 · limited partnership

As an employer

US visa salary filings

Job titleFilingsMedianRange
Senior AnalystLong Island City, NY 2 $160,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: Logos Global Management LP.

$545.1m reported value -29.3% vs Q1 2022
32positions
72.8%in top 10
4 new 7 added 16 reduced 19 sold out vs Q1 2022

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 CYTOKINETICS INC COM NEW CYTK CYTK 1,750,000 $68.8m12.61% 12.61% AddedShares held: Q3 2021 1.0m, Q4 2021 1.3m, Q1 2022 1.6m, Q2 2022 1.8m +135.0k +135,000 8.4%
2 APELLIS PHARMACEUTICALS INC COM APLS APLS 1,500,000 $67.8m12.44% 12.44% AddedShares held: Q3 2021 1.4m, Q4 2021 1.0m, Q1 2022 900.0k, Q2 2022 1.5m +600.0k +600,000 66.7%
3 IDEAYA BIOSCIENCES INC COM IDYA IDYA 3,750,000 $51.8m9.49% 9.49% AddedShares held: Q3 2021 1.8m, Q4 2021 1.6m, Q1 2022 2.9m, Q2 2022 3.8m +900.0k +900,000 31.6%
4 DESIGN THERAPEUTICS INC COM DSGN DSGN 2,797,501 $39.2m7.19% 7.19% UnchangedShares held: Q3 2021 2.8m, Q4 2021 2.8m, Q1 2022 2.8m, Q2 2022 2.8m
5 SAREPTA THERAPEUTICS INC COM SRPT SRPT 400,000 $30.0m5.50% 5.50% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 400.0k
6 NEUROCRINE BIOSCIENCES INC COM NBIX NBIX 300,000 $29.2m5.37% 5.37% ReducedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 475.0k, Q2 2022 300.0k -175.0k -175,000 -36.8%
7 BICYCLE THERAPEUTICS PLC SPONSORED ADS BCYC BCYC 1,700,000 $28.5m5.23% 5.23% AddedShares held: Q3 2021 1.5m, Q4 2021 870.0k, Q1 2022 950.0k, Q2 2022 1.7m +750.0k +750,000 79.0%
8 VENTYX BIOSCIENCES INC COM VTYX VTYX 2,312,680 $28.3m5.19% 5.19% ReducedShares held: Q3 2021 0, Q4 2021 1.8m, Q1 2022 2.5m, Q2 2022 2.3m -201.6k -201,600 -8.0%
9 HORIZON THERAPEUTICS PUB L SHS HZNP HZNP 350,000 $27.9m5.12% 5.12% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 350.0k
10 ALX ONCOLOGY HLDGS INC COM ALXO ALXO 3,136,352 $25.4m4.65% 4.65% AddedShares held: Q3 2021 3.2m, Q4 2021 2.9m, Q1 2022 3.0m, Q2 2022 3.1m +125.0k +125,000 4.2%
11 ARCUTIS BIOTHERAPEUTICS INC COM ARQT ARQT 1,000,000 $21.3m3.91% 3.91% ReducedShares held: Q3 2021 0, Q4 2021 250.0k, Q1 2022 1.5m, Q2 2022 1.0m -500.0k -500,000 -33.3%
12 DYNE THERAPEUTICS INC COM DYN DYN 2,900,000 $19.9m3.66% 3.66% AddedShares held: Q3 2021 3.6m, Q4 2021 3.2m, Q1 2022 2.7m, Q2 2022 2.9m +165.6k +165,608 6.1%
13 KARUNA THERAPEUTICS INC COM COM 150,000 $19.0m3.48% 3.48% ReducedShares held: Q3 2021 460.0k, Q4 2021 300.0k, Q1 2022 340.0k, Q2 2022 150.0k -190.0k -190,000 -55.9%
14 DICE THERAPEUTICS INC COM COM 985,251 $15.3m2.81% 2.81% ReducedShares held: Q3 2021 1.2m, Q4 2021 1.7m, Q1 2022 1.4m, Q2 2022 985.3k -400.0k -400,000 -28.9%
15 OLEMA PHARMACEUTICALS INC COM OLMA OLMA 3,743,875 $15.2m2.80% 2.80% UnchangedShares held: Q3 2021 3.7m, Q4 2021 3.7m, Q1 2022 3.7m, Q2 2022 3.7m
16 CHEMOCENTRYX INC COM CCXI CCXI 600,000 $14.9m2.73% 2.73% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 600.0k
17 FULCRUM THERAPEUTICS INC COM FULC FULC 1,950,000 $9.6m1.75% 1.75% AddedShares held: Q3 2021 0, Q4 2021 685.0k, Q1 2022 1.0m, Q2 2022 1.9m +950.0k +950,000 95.0%
18 ACADIA PHARMACEUTICALS INC COM ACAD ACAD 650,000 $9.2m1.68% 1.68% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 650.0k
19 KEZAR LIFE SCIENCES INC COM COM 950,000 $7.9m1.44% 1.44% ReducedShares held: Q3 2021 4.1m, Q4 2021 1.4m, Q1 2022 1.6m, Q2 2022 950.0k -664.0k -664,021 -41.1%
20 CENTURY THERAPEUTICS INC COM IPSC IPSC 476,559 $4.0m0.73% 0.73% ReducedShares held: Q3 2021 639.1k, Q4 2021 614.1k, Q1 2022 550.3k, Q2 2022 476.6k -73.7k -73,700 -13.4%
21 CENTESSA PHARMACEUTICALS PLC SPONSORED ADS SPONSORED ADS 399,801 $1.9m0.36% 0.36% ReducedShares held: Q3 2021 1.1m, Q4 2021 454.5k, Q1 2022 454.5k, Q2 2022 399.8k -54.7k -54,744 -12.0%
22 SPRUCE BIOSCIENCES INC COM COM 1,000,000 $1.7m0.32% 0.32% UnchangedShares held: Q3 2021 0, Q4 2021 1.1m, Q1 2022 1.0m, Q2 2022 1.0m
23 INSTIL BIO INC COM COM 369,800 $1.7m0.31% 0.31% ReducedShares held: Q3 2021 1.3m, Q4 2021 0, Q1 2022 377.1k, Q2 2022 369.8k -7.3k -7,291 -1.9%
24 TALARIS THERAPEUTICS INC COM COM 270,987 $1.2m0.22% 0.22% ReducedShares held: Q3 2021 507.9k, Q4 2021 329.0k, Q1 2022 306.2k, Q2 2022 271.0k -35.2k -35,249 -11.5%
25 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 150,000 $1.2m0.22% 0.22% ReducedShares held: Q3 2021 681.8k, Q4 2021 850.0k, Q1 2022 213.7k, Q2 2022 150.0k -63.7k -63,744 -29.8%
26 TYRA BIOSCIENCES INC COM TYRA TYRA 166,526 $1.2m0.22% 0.22% ReducedShares held: Q3 2021 1.0m, Q4 2021 473.4k, Q1 2022 252.7k, Q2 2022 166.5k -86.2k -86,200 -34.1%
27 LIANBIO SPONSORED ADS LIANY LIANY 394,486 $852.0k0.16% 0.16% ReducedShares held: Q3 2021 0, Q4 2021 412.8k, Q1 2022 412.8k, Q2 2022 394.5k -18.4k -18,351 -4.5%
28 ATHIRA PHARMA INC COM COM 220,000 $671.0k0.12% 0.12% ReducedShares held: Q3 2021 1.9m, Q4 2021 1.6m, Q1 2022 717.3k, Q2 2022 220.0k -497.3k -497,285 -69.3%
29 VIGIL NEUROSCIENCE INC COM VIGL VIGL 205,595 $530.0k0.10% 0.10% UnchangedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 205.6k, Q2 2022 205.6k
30 PYXIS ONCOLOGY INC COMMON STOCK PYXS PYXS 220,434 $525.0k0.10% 0.10% ReducedShares held: Q3 2021 0, Q4 2021 286.7k, Q1 2022 286.7k, Q2 2022 220.4k -66.2k -66,218 -23.1%
31 NUVALENT INC COM COM 33,887 $460.0k0.08% 0.08% ReducedShares held: Q3 2021 134.7k, Q4 2021 134.7k, Q1 2022 134.7k, Q2 2022 33.9k -100.8k -100,763 -74.8%
32 NUVATION BIO INC *W EXP 07/07/202 NUVB.WS NUVB.WS 66,666 $19.0k0.00% 0.00% UnchangedShares held: Q3 2021 66.7k, Q4 2021 66.7k, Q1 2022 66.7k, Q2 2022 66.7k

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
GLOBAL BLOOD THERAPEUTICS IN GBT GBT 1,250,000 $43.3m1.2m shares
IVERIC BIO INC OPHT OPHT 1,800,000 $30.3m1.8m shares
MIRATI THERAPEUTICS INC MRTX MRTX 350,000 $28.8m350.0k shares
ASCENDIS PHARMA A/S 175,000 $20.5m175.0k shares
IOVANCE BIOTHERAPEUTICS INC IOVA IOVA 1,000,000 $16.6m1.0m shares
JOUNCE THERAPEUTICS INC JNCE JNCE 1,400,000 $9.5m1.4m shares
VERA THERAPEUTICS INC VERA VERA 385,000 $9.0m385.0k shares
SCHOLAR ROCK HLDG CORP SRRK SRRK 675,000 $8.7m675.0k shares
ANAPTYSBIO INC ANAB ANAB 300,000 $7.4m300.0k shares
VERVE THERAPEUTICS INC 96,912 $2.2m96.9k shares
CULLINAN THERAPEUTICS INC CGEM CGEM 200,000 $2.1m200.0k shares
VERONA PHARMA PLC VRNA VRNA 300,000 $1.5m300.0k shares
VISTAGEN THERAPEUTICS INC VTGN VTGN 1,000,000 $1.2m1.0m shares
COGENT BIOSCIENCES INC COGT COGT 150,000 $1.1m150.0k shares
IKENA ONCOLOGY INC 178,281 $1.1m178.3k shares
BIOMEA FUSION INC BMEA BMEA 200,000 $892.0k200.0k shares
SOMALOGIC INC SLGC SLGC 100,000 $802.0k100.0k shares
RAIN ONCOLOGY INC 134,194 $680.0k134.2k shares
OMEGA THERAPEUTICS INC 12,986 $81.0k13.0k shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-08-17 ACHV 10.0%≈ $68.8m new 13G 2026-08-17
PALATIN TECHNOLOGIES INC PTN · 13G · filed 2026-05-15 PTN 9.9%≈ $2.0m no change 13G 2026-05-15
MINERVA NEUROSCIENCES INC NERV · 13G · filed 2026-02-17 NERV 9.9%≈ $24.6m new 13G 2026-02-17